|
|
Blood, 1 January 2004, Vol. 103, No. 1, pp. 78-84.
Prepublished online as a Blood First Edition Paper on September 11, 2003; DOI 10.1182/blood-2003-04-1311.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
William J. Hogan,
Michael Maris,
Barry Storer,
Brenda M. Sandmaier,
David G. Maloney,
H. Gary Schoch,
Ann E. Woolfrey,
Howard M. Shulman,
Rainer Storb, and
George B. McDonald
From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and Departments of Medicine, Pediatrics, and Pathology, University of Washington School of Medicine, Seattle.
Liver injury is a frequent, serious complication of allogeneic hematopoietic cell transplantation (HCT) following myeloablative preparative regimens. We sought to determine the frequency and severity of hepatic injury after nonmyeloablative conditioning and its relationship to outcomes. One hundred ninety-three consecutive patients who received 2 Gy total body irradiation with or without fludarabine were evaluated for end points related to liver injury. Patients with diseases treatable by HCT who were ineligible for conventional myeloablative allogeneic HCT because of advanced age and/or comorbid conditions were included. Fifty-one patients (26%) developed hyperbilirubinemia of 68.4 µM (4 mg/dL) or greater, most commonly resulting from cholestasis due to graft-versus-host disease (GVHD) or sepsis. Pretransplantation factors associated with liver dysfunction were a diagnosis of aggressive malignancy (hazard ratio [HR] 1.9; P = .04) and the inclusion of fludarabine in the conditioning regimen (HR 1.8; P = .07). Overall survival at 1 year was superior for patients who had maximal serum bilirubin levels in the normal (78%) or minimally elevated (22.23-66.69 µM [1.3-3.9 mg/dL]) ranges (69%) compared with those in the 68.4 to 117.99 µM (4-6.9 mg/dL; 20%), 119.7 to 169.29 µM (7.0-9.9 mg/dL; 17%), and 171.0 µM (10 mg/dL; 19%) or greater groups. In summary, significant jaundice occurred in 26% of patients and was predominantly due to cholestasis resulting from GVHD and/or sepsis. Aggressive malignancies (mainly advanced disease) and later development of jaundice after transplantation predicted inferior survival.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Kusumi, M. Kami, Y. Kanda, K. Seki, M. Fujiwara, R. Koyama, T. Komatsu, Y. Kodama, T. Matsumura, K. Yuji, et al.
Hepatic Injury Following Reduced-Intensity Unrelated Cord Blood Transplantation for Adult Patients with Hematological Diseases.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
5322 - 5322.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. A. Copelan
Hematopoietic stem-cell transplantation.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1813 - 1826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Scott and B. M. Sandmaier
Outcomes with Myeloid Malignancies
Hematology,
January 1, 2006;
2006(1):
381 - 389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Sorror, M. B. Maris, R. Storb, F. Baron, B. M. Sandmaier, D. G. Maloney, and B. Storer
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
Blood,
October 15, 2005;
106(8):
2912 - 2919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Cornelissen and B. Lowenberg
Role of Allogeneic Stem Cell Transplantation in Current Treatment of Acute Myeloid Leukemia
Hematology,
January 1, 2005;
2005(1):
151 - 155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Blood,
September 1, 2004;
104(5):
1550 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
